Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP<2.6) at week 121 SELECT-SWITCH is the first Phase 3b/4 head-to-head trial comparing TNF inhibitor cycling… Read More
Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year Second pivotal development program of… Read More
The Ontario Government has rolled out several health announcements in advance of the return of the Legislative Assembly next week. The Ontario Government will introduce legislation that moves forward on… Read More
The Danish biotech start-up aims to advance transformative therapies for patients worldwide The Denmark based biotech start-up Fuse Vectors has established R&D activities in the Netherlands. The company has located in the Dutch… Read More
CORD’s seed2STEM summer research program for high school youth has been awarded the City of Vancouver’s Leadership in Reconciliation Award for 2025. seed2STEM transforms reconciliation principles into action by creating… Read More
